Hemochromatosis is a primary iron overload syndrome that, if untreated, can result
in end-organ dysfunction, including hypogonadotropic hypogonadism.
1
Here we describe a case of missed diagnosis of hemochromatosis that was unmasked
by testosterone therapy in a man with hypogonadism.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Revisiting hereditary hemochromatosis: current concepts and progress.Am J Med. 2006; 119: 391-399
- Hemochromatosis and iron-overload screening in a racially diverse population.N Engl J Med. 2005; 352: 1769-1778
- Iron-overload-related disease in HFE hereditary hemochromatosis.N Engl J Med. 2008; 358: 221-230
- Effects of graded doses of testosterone on erythropoiesis in healthy young and older men.J Clin Endocrinol Metab. 2008; 93: 914-919
- Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline.J Clin Endocrinol Metab. 2010; 95: 2536-2559
Article info
Publication history
Published online: April 05, 2016
Footnotes
Funding: None.
Conflict of Interest: None.
Authorship: The author had access to the data and a role in writing the manuscript.
Identification
Copyright
Published by Elsevier Inc.
